Producer
Zoetis Inc.
Zoetis Inc. (Parsippany NJ; NYSE: ZTS; ~$8.5B revenue FY2024; founded 2013 as Pfizer Animal Health spinoff) is the world's largest animal health company — ~20% global animal health market — and the dominant US dairy pharmaceutical supplier. Zoetis's dairy-relevant products include Lutalyse (dinoprost tromethamine — a PGF2α prostaglandin used for estrus synchronization, abortion, and pyometra treatment), CIDR (controlled internal drug release — intravaginal progesterone device for reproductive synchronization), Excede (ceftiofur crystalline free acid — third-generation cephalosporin for bovine respiratory disease), Draxxin (tulathromycin — macrolide antibiotic), and Improvac (GnRH immunocastration vaccine). Zoetis was the animal health division of Pfizer — the largest animal health company in the world hidden inside the world's largest pharmaceutical company. The 2013 IPO (raising $2.2B) revealed the scale of veterinary pharmaceutical concentration for the first time. Zoetis operates manufacturing in Kalamazoo MI, Lincoln NE, Guarulhos Brazil, Olot Spain, and Suzhou China.
1
Inputs supplied
1
Goods downstream
3
Facilities
0
Stories
What they make
1 input Zoetis Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Zoetis Inc. makes, pick one to see the full supply chain.
Where they make it
3 facilities
Zoetis Kalamazoo Manufacturing Site (Kalamazoo, Michigan) →
USMichigan · manufacturing
Zoetis's largest US manufacturing site in Kalamazoo Michigan — inheriting Pfizer Animal Health's historical Kalamazoo pharmaceutical campus, which itself descends from the Upjohn Company (Kalamazoo's founding pharmaceutical firm, founded 1886, later merged into Pfizer 1995). Produces veterinary injectables, vaccines, and biologics including mastitis treatments and reproductive hormones for dairy cattle. The Kalamazoo site is co-located with Pfizer's legacy human pharmaceutical manufacturing — one of the few sites where human and veterinary pharmaceutical manufacturing share infrastructure and compliance culture. Source: https://www.zoetis.com/about-zoetis/our-locations/
Zoetis Lincoln Manufacturing Facility (Lincoln, Nebraska) →
USNebraska · manufacturing
Zoetis Lincoln Nebraska facility is the primary US manufacturing site for CIDR (controlled internal drug release) devices and reproductive hormone products for dairy cattle. The Lincoln site produces Lutalyse (dinoprost tromethamine — prostaglandin F2α) — the market-leading estrus synchronization pharmaceutical for dairy cattle. Nebraska is geographically central to US dairy and beef cattle production regions. Source: https://www.zoetis.com/about-zoetis/our-locations/
Zoetis Olot Manufacturing Site (Olot, Catalonia, Spain) →
ESCatalonia · manufacturing
Zoetis manufacturing facility in Olot, Catalonia Spain — serves European dairy pharmaceutical markets. Produces vaccines and anti-infectives including mastitis treatments (intramammary preparations) and reproductive pharmaceuticals for European dairy cattle operations. The Olot facility is notably close to HIPRA's headquarters (Amer, also in Girona province, Catalonia) — two competing animal health companies manufacturing dairy pharmaceuticals within the same Catalan province. Source: https://www.zoetis.com/about-zoetis/our-locations/
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Companion Animal Health
48%Cattle & Dairy
25%Swine Health
12%Poultry & Aquaculture
10%Other Livestock (Sheep, Horses)
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Concentration2013
Zoetis was the animal health division of Pfizer — operating invisibly inside the world's largest pharmaceutical company for decades — and its 2013 IPO (the largest US healthcare IPO since 2000 at $2.2B raised) was the first moment the scale of veterinary pharmaceutical concentration became publicly visible. At the time of the spinoff, Zoetis had ~$4.6B in annual revenue and was already the world's largest animal health company by a significant margin — yet virtually no investor, supply chain analyst, or policy researcher had ever analyzed it separately from Pfizer's aggregate financials. The Pfizer/Zoetis relationship also meant that the world's largest animal health company shared manufacturing infrastructure, regulatory teams, active pharmaceutical ingredient sourcing, and quality systems with the world's largest human pharmaceutical company. Post-spinoff, Zoetis had to rebuild independent API sourcing relationships, its own FDA/USDA regulatory affairs infrastructure, and standalone manufacturing compliance programs — while simultaneously maintaining Zoetis product supply continuity. The hidden-inside-Pfizer structure meant that for 30+ years, the single company controlling ~20% of global animal health pharmaceutical supply was never analyzed as a supply chain concentration risk — it was simply Pfizer's agricultural division in footnotes.
Zoetis Inc. ↗Did you know2024
Zoetis's Apoquel and Librela use JAK inhibitor (Janus kinase inhibitor) technology to treat allergic dermatitis in dogs and cats — the same mechanism underlying baricitinib and tofacitinib, which were the first JAK inhibitors studied for COVID-19 treatment and are now approved for rheumatoid arthritis. The pharma company that controls a large share of the food animal health supply chain (dairy, swine, poultry) is simultaneously the innovator of JAK inhibitor drugs for companion animals that are mechanistically related to leading human immunology drugs. Veterinary drug discovery is increasingly informing human drug development: the same mechanism of action in your dog's allergy pill was a key step toward human autoimmune and COVID treatment.
Zoetis Inc ↗Origin2023
Zoetis was spun off from Pfizer in February 2013 in one of the largest-ever biopharma spinoffs — Pfizer had accumulated a world-class animal health business (including Warner-Lambert's Parke-Davis Veterinary Division and Fort Dodge Animal Health) that it wanted to separate to focus on human pharmaceuticals post-Wyeth acquisition. The Zoetis IPO raised $2.2 billion at a $13.3 billion valuation. Pfizer Animal Health had roots going back to the 1940s when Pfizer's fermentation capabilities for penicillin production were adapted for veterinary antibiotics — the same fermentation infrastructure that produced WWII penicillin was the foundation for post-war animal health pharmaceutical manufacturing.
Zoetis Inc ↗